Circulating endothelial cell levels decrease after vasodilator therapy and are a biomarker of clinical worsening in refractory pulmonary hypertension in children

M. Levy, D. Bonnet, L. Mauge, C. d‘Audigier, D. Celermajer, P. Gaussem, D. Smadja (Paris, France)

Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Session: Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Session type: Poster Discussion
Number: 1503
Disease area: Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Levy, D. Bonnet, L. Mauge, C. d‘Audigier, D. Celermajer, P. Gaussem, D. Smadja (Paris, France). Circulating endothelial cell levels decrease after vasodilator therapy and are a biomarker of clinical worsening in refractory pulmonary hypertension in children. Eur Respir J 2012; 40: Suppl. 56, 1503

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Role of brain natriuretic peptide levels in predicting the acute clinical worsening episodes and response to iloprost infusion in patients with pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009


Features of endothelial dysfunction in patients with COPD in combination with arterial hypertension
Source: Eur Respir J 2007; 30: Suppl. 51, 768s
Year: 2007

Endothelin-1 and endothelin-3 plasma levels in severe idiopathic pulmonary arterial hypertension
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005


Changing serum cytokines levels in patients with idiopathic pulmonary arterial hypertension treated with bosentan
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012

The effect of augmentation therapy on systemic and pulmonary inflammation markers in α1-antitrypsin deficiency patients
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010

Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J, 57 (4) 2003201; 10.1183/13993003.03201-2020
Year: 2021



Effect of targeted therapy on circulating endothelial progenitor cells in precapillary pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012

Peripheral airway dysfunction persist after endothelin receptor antagonist therapy in patients with idiopathic pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary circulation
Year: 2009


Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
Source: Eur Respir J, 55 (6) 2000041; 10.1183/13993003.00041-2020
Year: 2020



Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020


Impact of long-term oxygen therapy on systemic inflammation, morphological changes of red blood cells, pulmonary hemodynamics and diaphragm function in patients with chronic obstructive pulmonary disease.
Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD
Year: 2018


Reduced pulmonary vascular response to hypoxia is associated with endothelial dysfunction in chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: Suppl. 33, 173s
Year: 2001

Elevated pulmonary vascular resistance predicts mortality in COPD patients
Source: Eur Respir J, 58 (2) 2100944; 10.1183/13993003.00944-2021
Year: 2021



Exercise dependence of serum NT-PROBNP levels in patients with precapillary pulmonary hypertension
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009


Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension
Source: Eur Respir J 2016; 48: 1514-1516
Year: 2016


Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 598s
Year: 2002

Serum levels of microRNA-125a are decreased in patients with precapillary pulmonary hypertension and correlate inversely with hemodynamics
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013

Simvastatin does not reduce levels of inflammatory blood markers in patients with stable chronic obstructive pulmonary disease
Source: Annual Congress 2008 - COPD
Year: 2008


Increased arterial remodelling in smokers and mild-moderate COPD patients are indicative of potential early onset of pulmonary hypertension.
Source: Virtual Congress 2021 – Mechanistic pathways in chronic and new lung diseases
Year: 2021